This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk17: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
spk16: Thank you, Stephen. Good afternoon, and thank you for joining us today to discuss Arrowhead's results for its fiscal 2023 third quarter ended June 30, 2023. With us today for management, our president and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter. Dr. Javier San Martin, our chief medical officer, who will provide an update on our mid and later stage clinical pipeline. Dr. James Hamilton, our chief of discovery and translational medicine, who will provide an update on our earlier stage programs. and Ken Muskowski, our Chief Financial Officer, who will give a review of the financials. In addition, Tracy Oliver, our Chief Commercial Officer, and Patrick O'Brien, our Chief Operating Officer and General Counsel, will both be available during the Q&A portion of the call. Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. I'd now like to turn the call over to Chris Anzalone, President and CEO of the company. Chris.
spk05: Thanks, Vince. Good afternoon, everyone, and thank you for joining us today. Our industry is built on promise. Sometimes this promise can be stunning and carry with it the possibility of saving the lives of some and drastically improving life for others. Arrowhead's mission is to bring important new medicines to the people who need them and save lives and alleviate suffering where we can. While this is our guiding principle and focusing on this promise has given us purpose and the motivation to, I believe, innovate at industry-leading levels and operate at speeds not seen before, it is not the only important focus for us. Another is risk. Our industry swims in a sea of risk. We recognize that in order to succeed, we need to appreciate the great promise in front of us, but focus on all the risks between the idea and the medicine ultimately given to a patient. We are idealists, but we are not naive. One of our most important jobs is to mitigate and decrease risk where we can. We have made great progress on this broad front since our last call, and this is how I would like to frame our discussion today. Let's begin with pulmonary. We believe we've taken an important step toward further de-risking the entire pulmonary franchise with the first chronic GLB toxicology results starting to come in. For Arrow MMP7, the no AAL, or no observed adverse effect level, was the highest dose we tested in our chronic rat study. In other words, even at the highest dose tested, we are not seeing anything that is deemed adverse. The highest dose represents what we believe would be substantially greater exposure than would be applied to humans. We're waiting for final rat data from the arrow rage chronic GLP TOC study, but that also is looking like the no AEL will be the highest dose we tested. We are still waiting for the nine month monkey data in both candidates, but our experience with arrow ENAC leads us to believe that the rat is the more sensitive species for these pulmonary TOC studies. So it is very encouraging to us that the rodent studies look so positive. This is potentially a big step forward for the platform. As you may recall, we saw lung inflammation in some of the chronic GLP-TOX doses for arrow ENAC in 2021. Based on our analysis of those results, we concluded that we needed to increase the potency of our pulmonary candidates, and we clearly did that with arrow MMP7, arrow RAGE, and arrow MUC5AC. We were optimistic that these improvements would translate into better chronic TOX results, but of course we couldn't know until the data came in. As we are now seeing preliminary data from those studies come in, we are increasingly confident the arrow MMP7 and likely arrow RAGE may have substantially wider tox windows than arrow ENAC did. And I believe this represents a significant de-risking event for the pulmonary franchise. We look forward to having complete rat and monkey chronic GLP tox data for arrow RAGE and arrow MMP7 in coming months. and expect to have chronic GLP-TOX data for arrow MUC5AC next year. Encouraging preliminary chronic GLP-TOX data follow prior de-risking events in the pulmonary franchise over the past quarter. Specifically, I believe the arrow rage clinical data indicate three important things. First, the safety and tolerability reports to date have been good and nothing surprising has emerged. This is always a critical first step for a new platform and every new drug. The activity data we have seen thus far have been impressive and showed continued dose response through the top dose level. After a single inhaled dose of 184 milligrams of AeroRage, we saw up to 95% knockdown with a mean of 90% in that cohort. Not only is this a high level of target gene knockdown, but it was extraordinarily consistent across participants in the cohort. Each subject had a good response. This is in the same ballpark as what we now expect with optimized liver targeted programs, and this is an important point. I think it is generally accepted that RNAi is a reliable modality to safely reduce expression of a target gene, and that when Arrowhead introduces a new liver program, there is high expectation, both internally and externally, that the drug candidate will reduce expression of the target protein as designed. I am hopeful that each new data set we are approaching with each, I'm sorry, I am hopeful that with each new data set that we are approaching this expectation in pulmonary. That is a giant leap forward and an important value inflection point. Lastly, we think the data also show that the duration of effect with arrow rage supports a dosing interval of two months or more. This is an important de-risking event because it limits accumulated drug exposure, increasing our confidence that the good safety profile seen thus far may continue during chronic treatment. It would also be a very patient-friendly dosing regimen. Derisking the pulmonary platform is important for its own sake. As we have said in the past, we see many potential drugs coming out of the franchise that could address a number of unmet medical needs, and we appear to be the only company able to effectively use RNAi in the lungs. The pulmonary franchise alone could be the basis of a large company. But it's also important as an example of how we seek to derisk our broader business. From our perspective, a one or two drug company is a bet, not a business. From the beginning, we have sought to create a broadly diversified business to increase the number of patients we serve, but also importantly, as a hedge against the unpredictability of biology. In our industry, the risk of failure is substantial, and our mitigation strategy has been part innovation and part brute force. We have sought to create a technological platform that works reliably and then move as fast as we can to create as many well-thought-out drug candidates as possible. We built and continue to refine and expand the reach of our TRMM platform. This is a modular, structurally simple system to one, address multiple cell types, which allows our therapies to go where a disease is in a way that other RNA companies do not. Two, move rapidly from idea to the clinic and then efficiently through mid and late stage clinical studies. And three, provide platform continuity and competence which gives us an enhanced expectation of success for new candidates that we believe far exceeds that of biotech broadly. Lessons learned developing each candidate informs the development of future candidates, so our expectation of success grows stronger over time. We believe this translates to the potential for more candidates to become approved therapies than industry average. Our 20 and 25 initiative follows this platform development and represents, to some extent, the brute force component of our broader risk mitigation strategy. We have platforms that appear to work well, so we have the responsibility to our patients and stakeholders to build as many new drugs as fast as we can. It is our goal to have 20 clinical stage or marketed products by the year 2025. Somewhat paradoxically, building such a large pipeline is part of our strategy to mitigate balance sheet risk. We are in a very expensive business, and one could argue that the best way to ensure we are properly capitalized to bring drugs to market is to have a small, focused pipeline. We reject that. Rather, we believe that well-thought-out drug candidates with greater than industry average chances of success can always find homes in partner companies' pipelines. As we mentioned at our analyst day in June, we have brought in nearly $1 billion in partnering capital over the past six years and have not raised equity capital for over three and a half years. In fact, GSK recently initiated a Phase IIb study of GSK4532990, formerly called AeroHSD, for the treatment of NASH, which earned us a $30 million milestone payment. In addition, Takeda initiated the Phase III Redwood study of Vizisoran, being developed as a potential treatment for Alpha-1a trypsin deficiency liver disease, which earned Arrowhead a $40 million milestone payment. We believe that partnering is a good cornerstone of a broader financing strategy and one that our platforms are uniquely suited for because of the quality of the candidates coming out of them and the scarcity of the companies that are skilled at generating RNAi-based therapeutics. Our partnering strategy includes existing partnerships that are maturing and therefore eliciting higher payments, new potential partnerships that could combine our platforms with a partner's target or set of targets, and new partnerships on existing programs in our pipeline. Regarding the latter, on our last earnings call, I discussed that at the time we had paused the CTA filing because of some inbound interest in partnering Aeroducts 4. We continued to explore those options. However, we decided to move forward with the Aeroducts 4 CTA filing ourselves. Partnering discussions can take time, and we don't ultimately know if they will translate into license agreements. We felt it did not make sense to further delay the CTA filing and the Phase 1 study. While partnering continues to be a cornerstone of our financing model, we are certainly cognizant of the risk of over-partnering. We believe the best way to build a lot of value quickly is to retain some wholly owned candidates and drive toward commercialization. Of course, there is substantial risk with this course, but over the past quarter, we believe we have taken some off the table. We completed enrollment in the Phase III Palisade study of AeroApoC3 in patients with familial chylomicronemia syndrome, or FCS. This is an important milestone for Arrowhead because it will likely be the first candidate and indication that we will seek regulatory approval for. The final study visit for the last patient in is scheduled for Q2 of 2024, so we expect to start the NDA process next year. In addition to FCS, we are currently working on the phase three plans for severe hyperglyceridemia and mixed dyslipidemia, which we will be discussing with regulators this year. Shortly after those discussions, we plan to start phase three studies for those larger indications. Our other wholly-owned cardiomyobolic candidate, AeroAng3, also had an important milestone during the quarter. We presented data at the European Atherosclerosis Society Congress demonstrating that AeroAng3 achieved LDL-C reductions of 44% to 48% when added to existing standard of care treatments. These results are similar to results seen in studies of an approved monoclonal antibody targeting AngPTL3 in patients with HOFH. These are important de-risking data as we move toward one or more phase three programs, which we are currently designing. we are actively working on go-to-market strategies for multiple candidates. We expect to have four drug candidates in phase three studies by the end of the year. Two of these are currently wholly owned, AeroApoC3 and AeroAng3, and a third, Vazisaran, is partnered with a 50-50 profit share in the U.S., so we have retained substantial economics. As I mentioned, we will have our first phase three registrational study readout mid-next year. for our AeroApoC3 program in FCS and expect an NDA soon thereafter. As we look at our pipeline, we expect additional NDA filing opportunities on a very regular basis going forward. Moving to our earlier stage pipeline, we filed two CTAs for two new programs targeting gene expression in two different tissue types. I already mentioned AeroDUX4 in skeletal muscle for the treatment of FSHD. and the other is aerosol 1 in the central nervous system for the treatment of ALS. We expect additional CTAs over the next few quarters using both the CNS and skeletal muscle platforms. Of course, these are early, but they represent important de-risking events for potential CNS and skeletal muscle franchises. As with our advances in pulmonary, these are also illustrative of our desire to expand the reach of our technology and decrease the overall the overall risk of our business by creating value across many different channels lastly beforehand the call over to javier i want to highlight the r d day that we hosted in june during that presentation which is still available to boot to view on our website we gave updates and had external kols talk about some existing clinical programs in cardiometabolic and pulmonary disease and discuss what's next for us in CNS tissue, including potentially systemic delivery and delivery to adipose tissue. The R&D day had a lot of detail. We are constantly pushing our technology forward and expanding its reach. With that overview, I'd now like to turn the call over to Dr. Javier San Martin. Javier?
spk14: Thank you, Chris, and good afternoon, everyone. The design, planning, and preparation of the late-stage studies of our cardiometabolic candidates, ARO-ApoC-3 and ARO-H3, is well underway. We're making good progress towards our goal of conducting multiple NO Phase II meeting with regulators this year and initiating multiple Phase III study late this year and early next year. We also intend to present final Phase II data at the American Heart Association meeting in November pending after acceptance for multiple studies for both aero-eposy-3 and aero-eng-3. Let's take a moment to review the various studies we have conducted, and then I will provide our current thinking around the Phase III studies, how the Phase III studies may look like for each clinical indication. I will start with ARO-ApoC-3. Our investigational RNAi therapeutic being developed as a treatment for patients with mixed dyslipidemia, severe hypertriglyceridemia, and familiar thalamicronymia syndrome. AeroApoC3 is designed to reduce production of apolipoprotein C3 or ApoC3, a component of triglycerides-rich lipoproteins, including very low-density lipoproteins or VLDL, and chylomacron is a key regulator of triglycerides metabolism. Knocking down the hepatic production of ApoC3 by RNAi results in reduced VLDL synthesis and assembly, enhanced breakdown of triglycerides-rich lipoproteins, and better clearance of VLDL and chylomericuremin via LPL-dependent and independent pathways. We view aeroepositry as having the potential to address many patients' population with various lipid disorders that can lead to different clinical complications and phenotypes. Familia chylomecronymia syndrome, or FCS, is characterized by extremely high DG levels, over 1,000 milligrams per deciliter and as high as 5,000 milligrams per deciliter, leading to high risk of acute pancreatitis that usually requires hospitalization and can be fatal. Patients with FCS may also experience chronic abdominal pain, and they have to adhere to a very strict diet with very low fat content, leading to impair their quality of life. FCS is a severe and ultra-rare genetic disease that affects to a few thousand patients in the U.S. Severe hyperpigmentary edema, or SHTG, is characterized by a marked elevation in TG levels, typically over 500 milligrams per deciliter, which can lead to increased risk of acute pancreatitis, as well as an increased risk of cardiovascular disease. This condition is estimated to affect several million patients in the U.S. Lastly, mixed dyslipidemia is defined as the presence of high LDL cholesterol combined with DGs, Raman cholesterol, and low HDL. The liquid profile is a major component of the risk factor for arteriosclerosis cardiovascular disease. There are likely tens of millions of patients in the U.S. with mixed dyslipidemia who are not adequately controlled with current standard of care. The studies of AeroApoC-3 that we have conducted or are planning to conduct for each population are as follows. For FCS, we are conducting the PALYC-A study, which is a Phase III placebo-controlled study to evaluate the efficacy and safety of AeroApoC-3 in adults with FCS. The primary endpoint for the study is percent change from baseline in fasting TG at month 10. The study was fully enrolled in May with a total of 75 subjects distributed across 39 different sites in 18 countries who were randomized to receive 25 milligrams of aeroeposy-3, 50 milligrams of aeroeposy-3, or matching placebo once every three months. This puts us on schedule for study completion in Q2 of 2024. a data readout shortly thereafter, and then NDA preparation for regulatory filings. Participants who complete the randomized portion of policies are also eligible to continue in an extension period where all participants will receive 808-PC-3. For SHTG, we're conducting the SHASTA II Phase II study in 229 patients randomized 3-to-1 to receive 10, 25, or 50 milligrams of 808-PC-3 or placebo on day one and week 12. Patients with FCS were excluded from this study. The primary endpoint is percent change from baseline fasting TG at week 24. SHASTA-2 was the study that enabled us to begin planning and design for our phase three plan in SHTG patients. The data strongly support advancement into phase three and we plan to present results at the American Heart Association in November. The current Phase III plan for SSG includes two separate studies, which will be called SHASTA III and SHASTA IV. The idea behind the two studies is to have, first, a faster path to regulatory submission with the SHASTA III study, a double-blind, 12-month randomized control study of approximately 600 patients with TGs greater than 500 milligrams per deciliter. We believe this study, plus the large safety database from our phase one and two studies, will be an appropriate package for the initial filing for the SHTG indication. The second study, SHASTA-4, is designed to investigate the effect of AeroApoC-3 in a more severe population at high risk of developing pancreatitis. SHASTA-4 will include patients with TG greater than 880 milligrams per deciliter and recent history of pancreatitis. The duration of the double-blind portion of the study will be two years, and it will be powered to detect difference in the incidence of pancreatitis. This data could enable label expansion to include the indication statement of pancreatitis risk reduction, a key clinical outcome relevant to patients and reimbursement authorities. We have made a lot of progress on the planning and design of these studies and intend to have discussion with regulators this year and move forward rapidly with studies initiation. We will provide more details on the studies when they begin. In the broader mixed dyslipidemia population, we are conducting the new phase two study in 653 patients randomized three to one to receive 10, 25, or 50 milligrams of aeroeposite or placebo on day one and at week 12. We include an additional cohort of participants receiving 50 milligrams on day one and week 24. The primary endpoint is presentation from baseline in FAST-NTG at week 24 with additional assessment of the changes in various lipid parameters such as LDL cholesterol, non-HDL-C, HDL, ApoV, and VLDL, and other biomarkers. Similar to the SHTG study results, we believe the Phase II data from the newer studies strongly support advancement into a Phase III study, and we also plan to present these results at the American Heart. The Phase III program for this population will be a cardiovascular outcome trial called Cascade. Aeroepositrin has demonstrated positive effect on several lipid parameters that represent residual risk factor for arteriosclerosis, cardiovascular disease, even after LDL is well controlled. The cascade study will select the patient population with high risk driven by the high TGs, renminb, cholesterol, and low HDR, all of which are effectively addressed by ARO-ApoC-3. The study will be designed in collaboration with an academic research organization, or ARO, We're working on all aspects of the study design, including selection of the patient population, understanding and modeling background events rates, the potential effect size, and with that information, we'll define the sample size and duration of exposure to be able to detect a clinically meaningful reduction in cardiovascular events. For a finalized agreement with the selected CRO and ARO to help us conduct this important study, were scheduled to engage with regulators later this year and plan to initiate the CASCA study in 2024. Our strategy for ARO-H3 is to progressively study it in larger and longer studies to potentially bring it to very high prevalence disease populations that currently do not have adequate treatment options. Our strategy for ARO-H3 is more focused on smaller, well-defined populations 8-OH-3 is being developed as a treatment for homozygous-familiar hypercholesterolemia, or HOFH, and potentially in the future, subsets of heterozygous-familiar hypercholesterolemia, or HEFH. Phase II program for 8-OH-3 involved two studies. There are just two, Phase II study in 204 patients with myxitis epidemia, and the gateway study in 18 patients with HOFH. Interim data from the Gateway study was presented at the 91st European Arteriosclerosis Society Congress in May of 2023. At study week 20, administration of 200 milligrams or 300 milligrams of ROH3 on day one and day eight four led to mean reductions in LDL cholesterol of 48.1% and 44% respectively. These reductions were achieved on top of continuous standard of care, including statins, cetamide, PCSK9 inhibitors, and aferesis. These results were on par with an approval monoclonal antibody that also targets NH-PTL3. 80H3 has a much more convenient and patient-friendly dosing regimen of one subcutaneous injection every three months versus the antibody, which requires an intravenous infusion once a month. who are currently working on the Phase III study design and plan for ROH3 in HOFH and assessing potential other populations for future studies. I spoke in a bit more detail on both ROH3 and ROH3 during our R&D day in June. I recommend you view the archived webcast or presentation slides on our website if you want more background on the biology of the target, some of the clinical data, the rationale for our belief in their potential, and more specific information about our plans for clinical development. The other late-stage program we're working on with our partner, Takeda, is for the treatment of AATD liver disease. In June, updated Phase II clinical data from the Sequoia study were presented at ESL Congress 2023, and another presentation. The clinical results from the Phase II sequelae study of facilicillin were clear and compelling. Facilicillin treatment demonstrates substantial effect on severe key markers of liver disease. Takeda has taken the leading conduct in the Phase III Redwood clinical study. It is designed to enroll 160 adult patients with F2 to F4 fibrosis. The primary endpoint of the study is to decrease from baseline of at least one stage at week 106 in patients with F2 and F3 fibrosis. Takeda is doing an outstanding job at bringing global sites online for the Redwood Study and enrolling patients efficiently. Additional information on the Redwood Study can be found at the RedwoodLiverStudy.com. I will now turn the call over to Dr. James Hamilton. James.
spk04: Thank you, Javier. Our pipeline of early stage clinical candidates now includes eight programs addressing various diseases with gene expression in four tissue types, including liver, lung, and now muscle and CNS. Of these eight programs, most are wholly owned and in our core areas of focus. They are in pulmonary, aero RAGE, aero MUC5AC, aero MMP7, in cardiometabolic, aro-PNPLA3, in neuromuscular, aro-DUX4, and aro-SOD1. And we also have aro-C3 for complement-mediated diseases and HZN457 partnered with Horizon for gout. In addition, we have many undisclosed preclinical programs that should continue to feed our pipeline for years to come. We are increasingly looking for opportunities to focus around core areas, and we are fortunate that our platform provides us with so many opportunities. Our discovery and clinical development teams continue to be highly productive and efficient. One main benefit of drug development based on a proprietary technology platform is that it allows us to apply learnings from prior programs to each new program. This makes us faster, more precise, and I believe yields drug candidates with a higher probability of success. The TRUM platform has given us that advantage for liver-directed programs for a few years now. We believe we are now in a period where those same advantages exist for lung-directed programs, and we have the potential to get there over the next couple years for muscle and CNS. We held a very comprehensive R&D day during the quarter, so I'm not going to review all of Arrowhead's discovery and early development programs. I'd like to focus on some important potentially de-risking data from our Arrow RAGE program. Arrow RAGE is our RNAi therapeutic candidate designed to reduce expression of the receptor for advanced glycation end products, or RAGE, as a potential treatment for inflammatory pulmonary diseases such as asthma. We are currently conducting a phase 1-2A clinical trial in normal healthy volunteers and in patients with mild to moderate asthma. We have also recently filed an amendment to add a cohort of asthma patients with high baseline levels of fractional exhaled nitric oxide or phenol, which is a biomarker for the degree of IL-13 driven type 2 inflammation in the lung. Let's talk briefly about what data we generated and reported at the R&D day. First, with respect to safety and tolerability, to date there have been no reported serious or severe adverse events, no study withdraws or drug discontinuations due to adverse events, and safety labs have shown no pattern of adverse changes. There has also been no change in the pattern of airway immune cells, and all chest X-rays have been read as normal. These encouraging results have also been generally consistent in the arrow MMP7 and arrow MUC5AC programs. With respect to activity, the results to date, especially at the highest dose level, have exceeded our estimates and really represent a best-case scenario for target engagement. We are measuring soluble RAGE protein, or SRAGE, in serum after multiple doses in both healthy volunteers and in patients. and in BALF after a single dose in healthy volunteers and after multiple doses at the top dose level. The mean maximum reduction in SRAGE at the 92 milligram dose level after two doses on days one and 29 was 80% with a maximum reduction of 90%, with a long duration of effect that supports every other month dosing. At the highest dose of 184 milligrams, we achieved a similar result after just a single dose, with mean SRAGE reduction of up to 76% and maximal reduction of 91%. We also observed continued dose response in BALF with a single inhaled dose of 184 milligrams, achieving mean reduction of 90% and maximal reduction of 95%. We are still collecting data that we intend to report on later this year, including presentations at the European Respiratory Society International Congress in September. We believe this is the first compelling clinical evidence of gene target silencing in the lung using siRNA. We also believe that these clinical results have a good chance of being predictive of clinical results in other pulmonary programs, including ARROW MUC5AC and ARROW MMP7, and additional undisclosed preclinical programs. And lastly, on RAGE, What data are we generating over the coming months? We will have the chronic monkey GOP toxicology results before the end of the year, which will be needed prior to phase two initiation. We will be getting additional longer-term follow-up and multiple-dose data at the highest doses in healthy volunteers and in patients later this year and into next year. lastly we'll be getting data from the high pheno cohorts which is designed to assess if rage knockdown leads to an il-13 specific anti-inflammatory effect this study is not long enough or large enough to expect an efficacy signal but signals of inflammatory pathway inhibition after short course of exposure would be a welcome result we expect these data in 2024. i also want to provide an update on our earliest clinical candidates During the last quarter, we filed CTAs for our first muscle and CNS candidates, AERODUX4 and AEROSOD1, respectively. AERODUX4 is the first clinical candidate utilizing the TRMM platform to target disease-associated genes in skeletal muscle. Aerodux-4 is an investigational RNAi therapeutic designed to reduce expression of the gene that encodes the human double homeobox-4 or Dux-4 protein as a potential treatment for fascioscapular humeral muscular dystrophy or FSHD. Ending regulatory clearance, we intend to proceed with a phase 1, 2A dose escalating study to evaluate Aerodux-4 in adult patients with FSHD type 1. The study is designed to enroll up to 52 patients. The other CTA filed during the quarter was for AROSOD1, the first therapeutic candidate designed for delivery to the CNS, again leveraging the TRIMM platform. AROSOD1 is designed to reduce expression of superoxide dismutase 1 or SOD1 in CNS as a potential treatment for patients with amyotrophic lateral sclerosis or ALS caused by SOD1 mutations. Pending regulatory clearance, we intend to proceed with a phase one dose escalating study to evaluate ARASOD1 in adult patients with ALS harboring a SOD1 mutation, which is considered to be causative of ALS. The study is designed to enroll up to 24 patients. I will now turn the call over to Ken Muszkowski. Ken.
spk03: Thank you, James, and good afternoon, everyone. As we reported today, our net loss for the quarter ended June 30, 2023 was 102.9 million or 96 cents per share based on 107 million fully diluted weighted average shares outstanding. This compares with a net loss of 72 million or 68 cents per share based on 105.8 million fully diluted weighted average shares outstanding for the quarter ended June 30, 2022. Revenue for the quarter ended June 30, 2023 was 15.8 million compared to 32.4 million for the quarter ended June 30, 2022. Revenue in the current period primarily relates to our collaboration agreement with Takeda. Revenue is recognized as we complete our performance obligations, which include managing the ongoing AAT Phase II clinical trials for Takeda. There remains $17 million of revenue to be recognized associated with the Takeda collaboration, which we anticipate will be recognized over the next year. Total operating expenses for the quarter ended June 30, 2023, for $118.5 million, compared with $105.3 million for the quarter ended June 30, 2022. The key drivers of this change were increased candidate costs partially offset by lower stock compensation expense. The increased candidate costs were primarily due to the progression of the company's pipeline of candidates into the into and through clinical trials, which resulted in higher outsourced clinical trial, toxicity study, and manufacturing costs. Net cash used in operating activities during the three months ended June 30, 2023 was 21.4 million, compared with net cash used in operating activities of 68.9 million for the three months ended June 30, 2022. We expect our operating cash burn to be $80 to $90 million next quarter. We expect to spend between $160 and $180 million over the next three quarters to complete our GMP manufacturing facility and related laboratories in Verona, Wisconsin. Turning to our balance sheet, our cash and investments total $494.5 million at June 30, 2023, compared to $482.3 million at September 30, 2022. The increase in our cash and investments was primarily related to the $250 million payment from Royalty Pharma, as well as other licensing cash inflows offset by our operating cash burn, along with continuing capital projects. Our common shares outstanding at June 30, 2023 were $107.1 million.
spk05: that brief overview i will now turn the call back to chris thanks ken we are well on our way to reaching our 2025 goal to grow our pipeline of rni therapeutics to a total of 20 clinical stage or marketed products in the year 2025. however pipeline expansion is just a means to an end the ultimate goal and the reason we continue to invest in expanding our platform discovering new candidates advancing our clinical programs, and streamlining the drug manufacturing process is that it allows us to get important new medicines to patients in need as quickly and efficiently as possible. Doing this will also create a sustainable business and provide a steady stream of commercial revenue, which we now have a better line of sight on and a plan that we are executing to get there. Thank you for joining us today, and I would now like to open the call to your questions. Operator?
spk17: Thank you. We will now conduct a question and answer session. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. We ask that you please limit your questions to one, and if you would like to ask another question, please re-queue.
spk18: Please stand by while we compile the Q&A roster. Our first question comes from Luca Isi of RBC Capital. Oh, great. Thanks so much for taking my question.
spk08: It's a quick one here. I'm wondering if you can comment on what was your reaction to the Roche and Alnilam's deal. I guess the question there is, is AGT a target that you may be willing to pursue? And two, how do you think about a read-through to your cardiovascular franchise? And then maybe a super quick one for Javier, for severe hypertriglyceridemia. I was under the impression that you were planning a single pivotal trial with triglycerides as a primary endpoint and pancreatitis as a secondary endpoint. However, it sounds today like you're playing two separate studies, so wondering what drove that change. Thanks so much.
spk05: Sure. So, I don't know that we have really a position on the Mahill and Roche deal. Good for them. We are not working on that target. It didn't fit into where we see opportunities in this space. And I don't think it reads through to our cardiometabolic assets. I think those are really orthogonal to each other. Javier, do you want to address this?
spk14: Yeah. So, hi, Luca. I think when we presented the clinical program for 808-PC-3 at the R&D day, I think I mentioned that we're doing two studies. The first one, which is the one that would be the primary source of registration, is the SHASTA-3, which is 600 patients approximately with TG higher than 500. But we will start in parallel the study SHASTA-4 in patients with higher TG levels and present TG. past history of pancreatitis. That study will be approximately 200 patients, and that will not be part of the initial filing, but it will be a subsequent interaction with the agency, hopefully to get pancreatitis risk reduction in that study and eventually add that to the label. So it was planned, but there is a sequence here. First, Shasta 3 registration, and second, Shasta 4 label expansion.
spk18: Okay. Thank you. One moment for our next question. Our next questions come from Maury Raycroft of Jefferies.
spk13: Hi. Congrats on the progress, and thanks for taking my questions. For your pulmonary platform, you've got the late-breaker title for your range program at ERS next month. How much asthma patient data can we expect in this update, or will it be longer-term follow-up from the SAD and MAD healthy volunteer part of the study? And then separately, wanted to clarify for the preclin tox studies, are those six months or 12 months? And it sounds like you're somewhat beyond where you were with ENAC on safety. Can you just elaborate more on that as it relates to the preclinical and clinical data that you've got so far?
spk04: Yeah, sure. I can take the first part of the question. The data that will be presented at European Respiratory is primarily an update on the healthy volunteer, sad and mad duration. We may have a little bit more duration data from the first patient cohort, the asthmatic patient cohort, but we won't have additional patient data at that time. And then regarding the tox studies, this is the six-month rat tox study that Chris was referring to for both RAGE and MMP7.
spk05: So we're still waiting on the nine-month monkey tox. And you mentioned that it sounds like we are beyond where we were with MMP7. potentially less material in all of these candidates in the chronic tox studies, and that appears to be bearing fruit for us.
spk13: Got it. Okay. Thanks for taking my questions. You're welcome.
spk17: All right. Thank you.
spk18: One moment for our next question. Our next question comes from Patrick Trucchio of HC Wainwright and Company.
spk10: James Jensen, Thanks. Good afternoon. Just a few follow-up questions. The first one is just around the AeroRage chronic tox data. Can you just clarify, is this data, would it be expected in the third quarter or fourth quarter of calendar 2023? And how would you expect it to differ for that which was reported from AeroENAC just in terms of how are the doses for these compounds compared to ENAC? in these studies specifically. And then separately, just also regarding the pulmonary programs in clinical development, you know, there are several, three programs in clinical development, at least one in preclinical development. Can you give us an idea of what targets you could include for your pulmonary platform as it expands? And to what degree would you be looking at targets with genetic or clinical validation as you look to build out this pulmonary pipeline going forward?
spk05: I'll take the second and James can take the first. I've got the easy one. The answer is, you know, we can't give you too much guidance on undisclosed targets. I get your point that, of course, we will be looking at genetically validated targets and clinically validated targets, and that is always our preference. You've heard us say before, our goal here is to take as little target risk as we can, and one way to do that is to work on the most validated targets that we can. So we will certainly be doing that. Will we expand beyond that into some targets that have less validation? Probably. But my hope is that we will, is that in the near to midterm at least, you know, the targets we're focusing on will be well validated. James, you want to address the tox?
spk04: Yeah, sure, Patrick. Thanks for the question. Regarding tox, so the doses are across the board lower for the new pulmonary programs. in terms of exposure, I think most importantly, less frequent. If you recall, we used a day one, two, three, every two week dosing regimen for ENAC. And then for our current programs, the dose frequency is spread out much less frequent. We're dosing either monthly or every two months in the chronic tox studies.
spk05: And if you look, if you compare the exposure, I want to say it spans from ENAC being four times to ENAC being 20 times the amount of material compared to the various newer compounds we're working on. And that is entirely a testament to how much more potent these follow-on compounds are.
spk18: Great. Thank you so much. You're welcome. Thank you. One moment while we queue our next question. Next question is from Kay Nakai of ChartOn.
spk06: Hi, thanks. Question about partnering specifically for the CV assets. You know, you're going to go it alone initially with some of these phase threes, but you do have an outcome study out there planned. If you see success going it alone, does that make it more or less likely that you'll want to partner to do an outcome study?
spk05: So we are planning on doing the outcome study for Arrow FSC3 by ourselves. We see that as a very interesting asset, and the data have been very compelling, so we are happy to take that on ourselves. It doesn't mean that we're not going to partner that at some point geographically, potentially. Who knows? But we are happy to take on the CBOT risk ourselves, and so that's our plan right now.
spk17: Okay, thanks.
spk18: You're welcome.
spk17: Thank you. One moment for our next question. Our next question comes from Edward Tintoff of Piper Sandler.
spk07: Great. Thank you very much. So much going on and excited about the progress. As we look at the pipeline, You know, what should we be expecting from C3? I know that we're in these patient cohorts now of C3 glomerulopathy and maybe IgA nephropathy. When could we get data from those, and what would be your ultimate view for advancing arrow C3 further? Thanks.
spk04: In terms of when we should get data, we're probably looking at end of next year, so end of 2024. And what was the other part of the question?
spk07: Just how would you anticipate progressing from there?
spk04: Yeah. I mean, I think it depends on what the data show us. I think there are several other examples out there of Phase III programs that are ongoing for IgA nephropathy. and C3 glomerulopathy with biomarkers as primary endpoints. So I think our late-stage programs would probably look something similar to those.
spk18: Okay, great. Thank you. Thank you.
spk17: Thank you.
spk18: One moment for our next question. Our next question comes from Mani Foryuhar of Lear Inc.
spk17: Partners.
spk02: Hey, guys. Thanks for taking the question. A quick one around how you think about building the CD side of the franchise. Could you lay out what your estimation is for what is that CVOT should cost and probably cascade now? Presumably, given that you plan to go it alone, I would assume that you've got a reasonable budget estimate for what that might cost. And can you walk us through sort of how we should think about sort of expansion in OPEX as you build out the infrastructure to support what will be a larger study than you guys have ever done standalone before?
spk05: Sure. So we can't give you Yes, we are putting together estimates about what that's going to cost. However, we still haven't had our end of phase two meeting with the FDA. We are putting together our proposal, and so I expect that we'll be speaking with them this year. Until we have that conversation, until we have feedback from them, it's going to be very difficult for us to give you good numbers just because, you know, because we want better clarity. We will be happy to give you some estimates, some guidance, you know, once we have those discussions. But at this point, it's a bit premature.
spk02: Okay, so we should expect some numerical guidance around that. Post the end of phase two meeting, is that a reasonable expectation for us to have?
spk05: Yes, I think that is reasonable. We need to have feedback from the FDA. We need to incorporate that into our plans and then have that filtered out into our budget. So sometime over the next couple of quarters, we We'll be happy to chat about it at that point.
spk02: Okay. That's helpful. Thanks, guys.
spk18: You're very welcome.
spk17: All right. Thank you.
spk18: One moment for our next question. Next question comes from Mike Olse of Morgan Stanley.
spk09: Hey, guys. Thanks for taking the question. Maybe just a follow-up on the pulmonary program, specifically to the MMP7 program. Can you just remind us when we might see the initial clinical data there, and should the focus be just on target knockdown, or are there other data points that we should be focused on as well? Thank you.
spk04: Yeah, I think so that as we had stated at the analyst day meeting, we really think the focus there should be on the patients, since those are the population that has upregulated MMP7 in the valve and in the serum. So that's what we'll be focusing on. We're still in the healthy volunteer component of the study. And so we don't know how the patient cohorts will enroll just yet. Depending on enrollment, it's conceivable we could have some data by end of next year.
spk02: Got it. Thank you.
spk17: All right, thank you. One moment for our next question. Our next question is from Tony of Bee Riley Securities.
spk15: Good afternoon, Tim. Thanks for taking our question. So maybe just on the penile high asthma patient cohorts that you're just starting to enroll, could you clarify the dose levels being looked at and sort of what initial number of patients you, you know, intend to have before you may look to disclose something externally. And if you could comment, you know, how this could be same or different relative to, you know, your execution on the mild to moderate asthma MAD patient cohort. And then I have a quick follow-up.
spk04: Sure. So there are the two highest dose levels is what we're looking at in the Pheno cohort. So that's the 92 and the 184 milligram dose levels that we studied in the Healthy Volunteers. We'll investigate those doses in the Pheno cohorts as well. And we're doing 16 per cohort. In terms of how many we'd have to have enrolled before we disclose data, I can't really give you a clear answer to that.
spk05: Yeah. I think we'll wait until that study is over.
spk15: Got it. And in terms of your asthma cohort data before the end of the year, could you just clarify, would you also include some valve bronchoscopy data also in addition to serum data on the higher dose levels? Just clarify that.
spk04: The asthma patients actually don't undergo bronchoscopy, so we don't have a BALF data from the asthma patients. It's only the only S4H measure we get is from the serum in the asthma patients.
spk15: Got it. And just lastly, on the financial, the two milestones earned from GSK and Takeda, could you just clarify how they will be sort of modeled on your P&L in terms of recorded revenue, amortization schedule, et cetera?
spk03: So those milestones have already been recorded in revenue. They're not amortized over time. We actually recorded those the quarter before last. We received the cash in this past quarter.
spk15: Understood.
spk18: Thanks for taking our questions. Thank you. Okay, thank you. One moment for our next question.
spk17: The next question comes from Ellie Merle of UBS.
spk01: Hey, guys. Thanks so much for taking the question. Just a follow-up on the pulmonary patient cohort timing. I guess for RAID, just where are you in the enrollment of those high phenocohorts? I think you just mentioned you had 16 per cohort. And then for MUC5AC, I guess, where are you in enrollment of the asthma patient cohorts? And have you started enrolling in the COPD cohorts? And then just for MUC5AC, what should we expect in terms of the timing of potential patient data there? Thanks.
spk04: So on the Pheno cohorts, those The amendments to add those cohorts, I think, are just, they've been filed, and so they're working their way through the various regulatory bodies and ethics committees. And we haven't enrolled any high-fino patients just yet. And then the MUC5AC patient cohorts, we're enrolling into the, actually, all the cohorts are open so that all, of the asthma patient cohorts are currently open for MUC5AC. And we'd be looking, assuming enrollment goes well, probably having data mid to late next year as well. And then your last question I believe was on the COPD cohorts for MUC5AC. That's a similar situation. to the FINO cohorts. We've got the amendments filed, and so those are working their way through to get ethics and regulatory approval. So we'd expect to have those being enrolled later this year, aiming to have data maybe end of next year.
spk18: Great. Thanks so much. All right. Thank you so much. One moment for our next question. Next question is from William Pickering of Bernstein.
spk11: Good afternoon. Thanks for taking my question. So on Adipose, you gave a really interesting update at the R&D day, but you didn't disclose the target. I was wondering what the next steps on that program are and when we might learn more about it. Thank you.
spk05: Yeah, we have not disclosed targets. We are still in the early days a bit with Adipose. We have some ideas for targets, but we are not prepared to show any more data there quite yet. My hope is that you'll start to hear more about the clinical plan for Adipose in 2024.
spk11: Got it. Thanks. And then on HEFH, it sounds like you've become less definitive on the path forward for ANG3 in that indication versus last year. I was wondering if you could just talk about sort of what aspects of your thinking have evolved and how sure you are that you will, in fact, take it forward to phase three.
spk14: Yeah. So I think the issue here is whether we can develop the indication of HEFH without a full cardiovascular outcome trial. And there is some precedents that support that and some others don't. So we are working our way to understand if there is a subpopulation of HEFH that can be pushed forward into a regulatory path without the requirement of a cardiovascular outcome trial. So that's kind of where we are right now.
spk11: Got it. Thank you so much.
spk17: Okay, thank you. One moment for our next question. Next question is from Luca Aisi for RBC Capital.
spk08: Oh, great. Thanks so much. Excuse me. And again, maybe circling back on RAGE, James or Javier, What are you hoping to see for the initial readout for Fino? I understand the follow-up will be short, but what levels do you anticipate at baseline, and what kind of reduction are you hoping to see there? Again, just trying to understand what's the bogey for initial success there. And then maybe, Ken, if I may, I think your prior 10-Q suggested that the bill to the facility in Verona, Wisconsin, was going to cost $200 million to $250 million. However, the 10-Q today suggested that number has gone up to $260 million to $280 million. One, is that correct? And if two, what drove that change? Thanks so much.
spk18: Ken, do you want to start with that?
spk03: So we have seen certain cost increases as well as about a quarter of a delay in that project. So you will see that that total cost comes in a bit higher than we had originally estimated. That's really it. Okay.
spk14: Yes. So, Luca, we do have a good point of reference for the phenotherapeutic effect, and that's the dupilumab and descrelumab programs in which they saw somewhere between 40 and 48 percent reduction. I don't recall which one, but that's the range that, you know, I think we believe will be convincing that the range inhibition, it does work through the IL-13. So, that's the range that we're seeing. I think the base is 20. Or greater than. Greater than 20, you know, people with eosinophilus greater than 200. It's the same population very much of those point of reference, if you will, studies, and we expect to see something similar.
spk18: Thanks so much. All right. Thank you. One moment for our last question. This question is from Brendan Smith of TD Cohen.
spk12: Hi, guys. Thanks for taking the questions. A couple of quick ones from us. First, just wanted to ask actually about some of the CNS programs that you alluded to that you're going to kind of announce and bring into the clinic over the next couple of years. Really, I guess, how are you kind of thinking about which indications to move there? Are you really thinking to focus more on final indications, given that the tissue is a little bit easier to get to? Or really, what is kind of your strategy in deciding where to go there, kind of just trying to understand where you think is especially right for RNAi? And then if I could just really quickly, I wanted to ask a little bit more about kind of your financing plan. Obviously, you have a decent balance sheet for now. But I mean, to your point, you haven't raised equity in a few years, but you have a fair number of important readouts coming up and a lot of studies going on. So as we're kind of just looking at cash burn over the next few years, what really is kind of your strategy for the next 18, 24 months?
spk05: Sure, I'll take that and then I'll let Javier and James take the prior one. So look, as I mentioned in the prepare remarks, partnering is really a cornerstone of our financing strategy. And so we are exploring a number of different options really as we speak that are important for us. There are also other avenues. We are also exploring the possibility of doing some specific product financing for APOC3. We know that's going to be a CBOT. We know that's going to be expensive. And we are exploring the cost of capital for financing that in return for some royalties on that product for some period of time, things of that nature. And I think that we can get a long way to our financing needs through those levers. And we are looking to pull those levers certainly in the near to midterm. I think it's important for us.
spk04: And then regards to the CNS targets, we're interested in targets that may involve the spinal cord, as you mentioned, but also targets in the cortex. We can get good knockdown in various parts of the cortex. And we're looking at some targets in the deeper brain, although that can be a little bit more challenging to achieve the same level of knockdown. And then we like, as we do for other tissue types, targets with a degree of genetic validation that are either genetically defined or have some level of genetic validation behind them, and preferably a degree of clinical validation with, you know, other modalities that are out there that have shown success that we could follow on.
spk18: All right, great. Thanks, guys.
spk17: Okay, thank you. I'm showing no further questions at this time. I would now like to turn the conference back to Chris Anzalone for closing remarks.
spk18: Thanks, everyone, for joining us today, and I hope you have an enjoyable summer, and we look forward to talking to you soon.
spk17: All right, this concludes today's conference call. Thank you for participating. You may now disconnect.
Disclaimer